![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PELI2 |
Gene summary for PELI2 |
![]() |
Gene information | Species | Human | Gene symbol | PELI2 | Gene ID | 57161 |
Gene name | pellino E3 ubiquitin protein ligase family member 2 | |
Gene Alias | PELI2 | |
Cytomap | 14q22.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9H716 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57161 | PELI2 | CCI_1 | Human | Cervix | CC | 1.63e-13 | 9.06e-01 | 0.528 |
57161 | PELI2 | CCI_2 | Human | Cervix | CC | 3.07e-08 | 1.17e+00 | 0.5249 |
57161 | PELI2 | CCI_3 | Human | Cervix | CC | 9.89e-06 | 4.16e-01 | 0.516 |
57161 | PELI2 | AEH-subject1 | Human | Endometrium | AEH | 5.13e-04 | 2.41e-01 | -0.3059 |
57161 | PELI2 | AEH-subject4 | Human | Endometrium | AEH | 5.31e-08 | 3.99e-01 | -0.2657 |
57161 | PELI2 | AEH-subject5 | Human | Endometrium | AEH | 3.09e-15 | 5.81e-01 | -0.2953 |
57161 | PELI2 | EEC-subject1 | Human | Endometrium | EEC | 2.08e-02 | 2.58e-01 | -0.2682 |
57161 | PELI2 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.29e-02 | -7.54e-02 | -0.1934 |
57161 | PELI2 | LZE24T | Human | Esophagus | ESCC | 3.33e-16 | 4.30e-01 | 0.0596 |
57161 | PELI2 | P2T-E | Human | Esophagus | ESCC | 1.83e-08 | 1.79e-01 | 0.1177 |
57161 | PELI2 | P8T-E | Human | Esophagus | ESCC | 6.82e-11 | 2.10e-01 | 0.0889 |
57161 | PELI2 | P9T-E | Human | Esophagus | ESCC | 1.86e-06 | 1.91e-01 | 0.1131 |
57161 | PELI2 | P10T-E | Human | Esophagus | ESCC | 6.02e-25 | 3.86e-01 | 0.116 |
57161 | PELI2 | P12T-E | Human | Esophagus | ESCC | 4.80e-26 | 5.43e-01 | 0.1122 |
57161 | PELI2 | P15T-E | Human | Esophagus | ESCC | 2.02e-29 | 6.55e-01 | 0.1149 |
57161 | PELI2 | P16T-E | Human | Esophagus | ESCC | 4.46e-05 | 1.31e-01 | 0.1153 |
57161 | PELI2 | P22T-E | Human | Esophagus | ESCC | 1.39e-09 | 9.72e-02 | 0.1236 |
57161 | PELI2 | P23T-E | Human | Esophagus | ESCC | 2.30e-04 | 1.35e-01 | 0.108 |
57161 | PELI2 | P26T-E | Human | Esophagus | ESCC | 1.21e-44 | 6.73e-01 | 0.1276 |
57161 | PELI2 | P27T-E | Human | Esophagus | ESCC | 1.09e-12 | 1.63e-01 | 0.1055 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000020924 | Skin | cSCC | protein polyubiquitination | 103/4864 | 236/18723 | 2.57e-09 | 9.09e-08 | 103 |
GO:0043123110 | Skin | cSCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 84/4864 | 186/18723 | 1.09e-08 | 3.40e-07 | 84 |
GO:000724925 | Skin | cSCC | I-kappaB kinase/NF-kappaB signaling | 116/4864 | 281/18723 | 1.33e-08 | 4.08e-07 | 116 |
GO:004312225 | Skin | cSCC | regulation of I-kappaB kinase/NF-kappaB signaling | 105/4864 | 249/18723 | 1.70e-08 | 5.09e-07 | 105 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PELI2 | SNV | Missense_Mutation | rs749388627 | c.686N>A | p.Arg229Gln | p.R229Q | Q9HAT8 | protein_coding | deleterious(0.05) | possibly_damaging(0.582) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
PELI2 | SNV | Missense_Mutation | novel | c.416T>A | p.Phe139Tyr | p.F139Y | Q9HAT8 | protein_coding | tolerated(0.39) | benign(0.019) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PELI2 | SNV | Missense_Mutation | rs200311934 | c.974G>A | p.Arg325Gln | p.R325Q | Q9HAT8 | protein_coding | tolerated(0.24) | possibly_damaging(0.598) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
PELI2 | SNV | Missense_Mutation | c.801N>C | p.Gln267His | p.Q267H | Q9HAT8 | protein_coding | tolerated(0.51) | possibly_damaging(0.77) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PELI2 | SNV | Missense_Mutation | c.841C>T | p.Arg281Trp | p.R281W | Q9HAT8 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | |
PELI2 | SNV | Missense_Mutation | rs557894615 | c.601N>A | p.Glu201Lys | p.E201K | Q9HAT8 | protein_coding | tolerated(0.44) | benign(0.146) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PELI2 | insertion | Frame_Shift_Ins | novel | c.978_979insATCTTCAAATATTTTTTTGCTTGTTCTGAGAGGAAAGAATCTTGGA | p.Asp327IlefsTer41 | p.D327Ifs*41 | Q9HAT8 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
PELI2 | SNV | Missense_Mutation | novel | c.1187C>G | p.Ala396Gly | p.A396G | Q9HAT8 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PELI2 | SNV | Missense_Mutation | c.275N>G | p.Glu92Gly | p.E92G | Q9HAT8 | protein_coding | deleterious(0.02) | probably_damaging(0.922) | TCGA-EA-A3HQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PELI2 | SNV | Missense_Mutation | rs375391259 | c.616N>A | p.Gly206Arg | p.G206R | Q9HAT8 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-JW-A852-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |